Titanovo Logo
Back to Cell Types

SW780Homo sapiens (Human)Cancer cell line

Also known as: SW 780, SW-780

🤖 AI SummaryBased on 14 publications

Quick Overview

Bladder cancer cell line for research on tumor biology and drug response.

Detailed Summary

SW780 is a human bladder cancer cell line derived from a transitional cell carcinoma. It is widely used in research to study the molecular mechanisms of bladder cancer, including the role of the FOXP3A3 isoform in chemotherapy resistance and tumor differentiation. SW780 has been utilized in studies examining genomic alterations, such as mutations in the TERT promoter and other key cancer-related genes. This cell line is also employed in investigations of the PI3K/mTOR and MAPK signaling pathways, as well as in the development of predictive models for drug sensitivity. Its utility in understanding the genetic and molecular basis of bladder cancer makes it a valuable resource for cancer research.

Research Applications

Molecular mechanisms of bladder cancerFOXP3A3 isoform in chemotherapy resistanceGenomic alterations and mutationsPI3K/mTOR and MAPK signaling pathwaysPredictive models for drug sensitivity

Key Characteristics

Expresses FOXP3A3 isoformTERT promoter mutationsGenomic instability and mutations in cancer-related genesUtilized in drug response studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1728
SpeciesHomo sapiens (Human)
Tissue SourceUrinary bladder[UBERON:UBERON_0001255]

Donor Information

Age80
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeATCC
Source IDACH-000384_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,11
D13S317
11,12
D16S539
9,11
D18S51
15
D19S433
13,15
D21S11
29,30
D2S1338
19,22
D3S1358
16,18
D5S818
11,12
D7S820
9,10
D8S1179
13
FGA
19,20
Penta D
9
Penta E
12
TH01
6
TPOX
8
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

Oncogene 36:35-46(2017).

DOIPubMedPMC

Biased expression of the FOXP3Delta3 isoform in aggressive bladder cancer mediates differentiation and cisplatin chemotherapy resistance.

Huang J.-T., Li G., Pellegrini M., Chin A.I.

Clin. Cancer Res. 22:5349-5361(2016).

DOIPubMed

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Chanock S.J., Valencia A., Real F.X.

BMC Genomics 16:403.1-403.16(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

DOIPubMedPMC

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

DOIPubMed

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.

Eur. Urol. 65:360-366(2014).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

PubMed

Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice.

Kyriazis A.A., Kyriazis A.P., McCombs W.B. 3rd, Peterson W.D. Jr.

Cancer Res. 44:3997-4005(1984).

PubMed

Human urologic cancer cell lines.";

Williams R.D.

Invest. Urol. 17:359-363(1980).

PubMed

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

DOIPubMed

Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.

Kerbel R.S., Pross H.F., Leibovitz A.

Int. J. Cancer 20:673-679(1977).

DOIPubMed

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

DOIPubMed

Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.

Fogh J.

Natl. Cancer Inst. Monogr. 49:5-9(1978).

PubMed

Web Resources

synapse.org